Rhopressa

Chemical NameKinase inhibitors
Dosage FormDrops (eye; 0.02%)
Drug ClassKinase inhibitors
SystemOcular
CompanyAerie Pharmaceutical Inc.
Approval Year2017

Indication

  • For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rhopressa (netarsudil) Prescribing Information2019Aerie Pharmaceuticals, Inc., Irvine, CA